Brief: Wockhardt Says Completion Of Phase 3 Pneumonia Study Of Nafithromycin Wck 4873
11/12/2023 06:30
Dec 11 (Reuters) - Wockhardt Ltd WCKH.NS :
* COMPLETION OF PHASE 3 PNEUMONIA STUDY OF MACROLIDE
ANTIBIOTIC
NAFITHROMYCIN WCK 4873
Source text for Eikon: ID:nNSEMjgpF
Further company coverage: WCKH.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Wockhardt
See all newsBrief: Wockhardt Says Customs Authority Imposes 50 Million Rupees Penalty And 100 Million Rupees Redemption Fine On Co
Brief: Wockhardt Limited June-Quarter Consol Net Profit 1.06 Billion Rupees
India's Wockhardt gains after marketing authorization for antibiotic ZAYNICH
Brief: Wockhardt Says Indian Drug Regulator Grants Marketing Authorization To Co's Zaynich
India's Wockhardt hits 7‑month high after swinging to profit in fourth quarter